Press Releases

Achieved Primary 30 Day Endpoint   Patients in CARENET Trial had significantly lower incidence of new ischemic lesions    compared to historical control groups of non-mesh covered carotid stents   BOSTON, MA – September 16, 2014 — InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced positive results… Read More

BOSTON, MA – September 03, 2014 — InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced that its Chief Financial Officer, Craig Shore, will be presenting at the Aegis Healthcare and Technology Conference at the Encore at Wynn Las Vegas. The Company will present on Friday, September… Read More

Results will be announced on Tuesday, September 16in Washington, D.C. BOSTON, MA – August 11, 2014 — InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced that Professor Joachim Schofer, MD, at the Hamburg University Cardiovascular Center, will present the results of the CARENET (CARotid Embolic protection… Read More

BOSTON, MA – July 23, 2014 – InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced its financial and operating results for the second quarter, which ended June 30, 2014. Recent Operating Highlights   Received European approval to resume manufacturing and distribution of MGuard™ Prime EPS  … Read More

BOSTON, MA – July 17, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems, announced today that it will release its financial results for the second quarter ended June 30, 2014 on Wednesday, July 23rd. The Company will host a conference call at 4:30 p.m. ET on… Read More

Strengthens Leadership Team with Addition of Experienced Medical Device Executive   BOSTON, MA – July 15, 2014 – InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems, today announced the appointment of James Barry, Ph.D. as Chief Operating Officer. Barry, who has more than two decades of experience in the… Read More

100% procedural success rate achieved in first multi-specialty clinical experience BOSTON, MA – July 8, 2014 — InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced that it has concluded enrollment in its CARENET clinical trial. The multi-specialty (Interventional Cardiologists, Interventional Radiologists and Vascular Surgeons) trial is… Read More

BOSTON, MA – July 1, 2014 — InspireMD Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems, today announced that it has been selected to join the Russell MicrocapIndex, as of June 27, 2014. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in… Read More

BOSTON, MA – June 23, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (EPS), today announced that it received European regulatory approval to resume the manufacturing of its MGuard Prime EPS stent with a modified stent securement process . The Company also received approval to modify and re-deploy existing… Read More

BOSTON, MA – June 18, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), today announced that its CEO, Alan Milinazzo, will be presenting at the 9th Annual JMP Securities Healthcare Conference at the Westin New York Grand Central in New York. The Company will present at 11:00 a.m. ET on Wednesday, June… Read More